RxDoctor Payments Data

Richard Dellinger, DPM

Foot & Ankle Surgery · Little Rock, ARNPI 1407814940

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 69 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 20 manufacturers reported payments, led by Amgen at 35.3% of the total. Reporting peaked in 2022 at $394 and has fallen 83.9% since, to $63 in 2025. That places this record below the midpoint for foot & ankle surgery clinicians in AR, where the typical reported total is $2,601.

$1,713in general payments, 2019–2025

Across 69 payments — averaging $24.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$604
  • Nevro Corp.$350
  • Paratek Pharmaceuticals, Inc.$156
  • Paragon 28, Inc.$146
  • Smith+Nephew$74
  • Progenacare Global, LLC$48
  • plus $335 from 14 others
$30,490in research payments, 2019–2025

Across 7 payments — averaging $4355.76 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Ipsen Innovation$19K
  • Amgen$11K

What the payments were for

  • Food & beverage$1,713100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,713 in reported general payments places this provider in the 40th percentile of 35 foot & ankle surgery providers in Arkansas.

See all foot & ankle surgery providers in Arkansas

Medicare billing

Part B allowed, 2024
$127,788
Medicare patients
617
Services billed
2,132

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Terbinafine Hcl79$621
Clindamycin Hcl16$217
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen28$181
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim12$56
Tramadol Hcl21$30

Paid to pharmacies, not to this prescriber.

Other foot & ankle surgery in Little Rock

See the full list for Arkansas

Where these figures come from

Is this you, or does something look wrong? →